Haemonetics (NYSE:HAE) Issues FY 2027 Earnings Guidance

Haemonetics (NYSE:HAE) issued an update on its FY 2027 earnings guidance on Thursday morning. The company provided EPS guidance of 5.258-5.307 for the period, compared to the consensus EPS estimate of 5.290. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Haemonetics Stock Up 1.3%

Shares of Haemonetics stock traded up $0.69 during trading on Friday, reaching $55.06. The company’s stock had a trading volume of 789,043 shares, compared to its average volume of 827,910. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01. The company has a market cap of $2.56 billion, a price-to-earnings ratio of 15.17, a P/E/G ratio of 1.03 and a beta of 0.53. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32. The company has a 50-day simple moving average of $59.53 and a two-hundred day simple moving average of $66.68.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. The firm had revenue of $346.35 million during the quarter, compared to analysts’ expectations of $336.83 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, equities analysts forecast that Haemonetics will post 4.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on HAE shares. JPMorgan Chase & Co. lowered their price objective on Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research report on Friday. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. BTIG Research reissued a “buy” rating and issued a $88.00 price objective on shares of Haemonetics in a research report on Friday, February 6th. Robert W. Baird set a $67.00 price target on Haemonetics in a research report on Friday. Finally, Citigroup lowered their price target on Haemonetics from $75.00 to $70.00 and set a “neutral” rating for the company in a research report on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and an average price target of $79.89.

Key Headlines Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Q4 results beat consensus: Haemonetics reported $1.29 EPS and $346.4M revenue (both ahead of Street estimates), with revenue up ~4.8% year-over-year — a core reason investors are bidding the stock up. Haemonetics (NYSE:HAE) Reports Upbeat Q1 CY2026
• Positive Sentiment: Management expects FY2027 revenue growth of 4%–7%, citing continued Persona PLUS rollout and efforts to rebound IVT volumes — these operational drivers support the growth narrative that investors are rewarding. Haemonetics projects FY 2027 revenue growth of 4% to 7%…
• Positive Sentiment: Outside buying signal: The London Company’s Small Cap Portfolio added to Haemonetics following recent volatility, indicating some institutional interest that can lift sentiment and trading. The London Company Small Cap Portfolio Q1 2026 Portfolio Review
• Neutral Sentiment: FY2027 EPS guidance band (5.258–5.307) is roughly in line with consensus (about 5.29), so while guidance supports stability, it doesn’t represent a clear upside surprise versus expectations. PR Newswire: Financial results available
• Neutral Sentiment: Investors can review the full earnings call transcript and supplemental materials for management commentary and cadence on Persona PLUS and IVT recovery; these details will shape whether the current upbeat reaction sustains. Haemonetics Q4 2026 Earnings Call Transcript

Hedge Funds Weigh In On Haemonetics

Several institutional investors and hedge funds have recently modified their holdings of HAE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Haemonetics by 3.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock valued at $1,877,000 after buying an additional 971 shares during the period. Caxton Associates LLP acquired a new position in shares of Haemonetics in the 1st quarter valued at about $216,000. United Services Automobile Association acquired a new position in shares of Haemonetics in the 1st quarter valued at about $212,000. Empowered Funds LLC lifted its holdings in shares of Haemonetics by 9.1% in the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after buying an additional 372 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Haemonetics by 6.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock valued at $9,923,000 after buying an additional 9,051 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.